+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years +
All Genders
ID07849231

Evaluating Safety and Early Effects of DMR-001 Alone or With Ruxolitinib in Adults With CALR-mutant Myeloproliferative Neoplasms

Led by Damora Therapeutics · Updated on 2026-10-27

250

Participants Needed

36

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety, pharmacokinetics, immune response, and early effects of the investigational drug DMR-001 in adults with CALR-mutated myeloproliferative neoplasms, including essential thrombocythemia ET and myelofibrosis MF. The study also assesses DMR-001 combined with ruxolitinib in patients with CALR-mutant MF. This Phase 11b open-label study aims to determine recommended dosing levels and preliminary clinical activity. DMR-001 is given as a subcutaneous injection once every four weeks in several parts of the trial an initial dose escalation phase to find safe doses, a dose expansion phase using those doses, and a combination phase where DMR-001 is administered with ruxolitinib, an approved oral therapy for MF. The combination and monotherapy dosing schedules are carefully monitored to identify the maximum tolerated doses and recommended doses for future studies. Participants will be closely monitored for safety and treatment effects for up to 672 days. This includes laboratory tests, bone marrow biopsies, and pharmacokinetic assessments to measure drug levels and immune response. Researchers will assess tolerability, clinical activity, and immune reactions to DMR-001 alone or combined with ruxolitinib. The study involves regular visits for treatment administration and safety evaluations, ensuring continuous observation throughout the trial period.

CONDITIONS

Brief Title

A Study to Evaluate DMR-001 in Participants With CALR-mutant Myeloproliferative Neoplasms

Research Team

D

Damora Therapeutics Medical Monitor

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here